Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 7, 2016

Study Completion Date

July 7, 2016

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Sensoril®

Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera

DRUG

Placebo

Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.

Trial Locations (1)

15213

Western Psychiatric Institute & Clinic, Pittsburgh

All Listed Sponsors
lead

K.N. Roy Chengappa

OTHER

NCT01793935 - Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia | Biotech Hunter | Biotech Hunter